Identification of new 4-(6-oxopyridazin-1-yl)benzenesulfonamides as multi-target anti-inflammatory agents targeting carbonic anhydrase, COX-2 and 5-LOX enzymes: synthesis, biological evaluations and modelling insights
暂无分享,去创建一个
C. Supuran | Mohamed Elagawany | Wagdy M. Eldehna | A. Nocentini | P. Gratteri | Sara T. A. Al-Rashood | Alessandro Bonardi | M. Abd-Alhaseeb | E. Elkaeed | Giri Babu Veerakanellore | Waleed A Badawi | Taghreed A. Majrashi | Mahmoud Rashed | Bahaa Elgendy
[1] C. Supuran,et al. 4-(5-Amino-pyrazol-1-yl)benzenesulfonamide derivatives as novel multi-target anti-inflammatory agents endowed with inhibitory activity against COX-2, 5-LOX and carbonic anhydrase: Design, synthesis, and biological assessments. , 2023, European journal of medicinal chemistry.
[2] A. Nafady,et al. Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities. , 2022, Bioorganic chemistry.
[3] A. Khlebnikov,et al. Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity , 2022, Molecules.
[4] A. El-Malah,et al. Anti‐inflammatory activity of pyridazinones: A review , 2022, Archiv der Pharmazie.
[5] C. Supuran. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors , 2021, Expert opinion on investigational drugs.
[6] Venkata Rao Kaki,et al. Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR. , 2021, European journal of medicinal chemistry.
[7] C. Supuran,et al. Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development. , 2021, Pharmacology & therapeutics.
[8] Tamer M. Ibrahim,et al. Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors. , 2021, European journal of medicinal chemistry.
[9] C. Supuran. Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders , 2021, Journal of enzyme inhibition and medicinal chemistry.
[10] C. Supuran,et al. An overview on the recently discovered iota-carbonic anhydrases , 2021, Journal of enzyme inhibition and medicinal chemistry.
[11] David S. Goodsell,et al. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences , 2020, Nucleic Acids Res..
[12] S. Carradori,et al. Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment , 2020, Metabolites.
[13] C. Supuran,et al. 3-Methylthiazolo[3,2-a]benzimidazole-benzenesulfonamide conjugates as novel carbonic anhydrase inhibitors endowed with anticancer activity: Design, synthesis, biological and molecular modeling studies. , 2020, European journal of medicinal chemistry.
[14] U. Farooq,et al. Benzylaminoethyureido-Tailed Benzenesulfonamides: Design, Synthesis, Kinetic and X-ray Investigations on Human Carbonic Anhydrases , 2020, International journal of molecular sciences.
[15] C. Supuran,et al. Benzofuran-Based Carboxylic Acids as Carbonic Anhydrase Inhibitors and Antiproliferative Agents against Breast Cancer. , 2020, ACS medicinal chemistry letters.
[16] C. Supuran,et al. Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells. , 2020, European journal of medicinal chemistry.
[17] M. Abd-Alhaseeb,et al. Synthesis and biological screening of some novel 6‐substituted 2‐alkylpyridazin‐3(2H)‐ones as anti‐inflammatory and analgesic agents , 2020, Archiv der Pharmazie.
[18] A. El-Malah,et al. Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents. , 2019, European journal of medicinal chemistry.
[19] C. Supuran,et al. Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines. , 2019, European journal of medicinal chemistry.
[20] M. Bolognesi,et al. Editorial: Multi-Target-Directed Ligands (MTDL) as Challenging Research Tools in Drug Discovery: From Design to Pharmacological Evaluation , 2019, Front. Chem..
[21] C. Supuran,et al. Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamides as carbonic anhydrase isoforms I and II inhibitors , 2019, Journal of enzyme inhibition and medicinal chemistry.
[22] K. R. Ethiraj,et al. Safer anti‐inflammatory therapy through dual COX‐2/5‐LOX inhibitors: A structure‐based approach , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[23] M. Médebielle,et al. Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents. , 2018, European journal of medicinal chemistry.
[24] M. Ghoneim,et al. Synthesis and Anticancer Studies of Novel N-benzyl Pyridazino ne Derivatives , 2017 .
[25] M. Said,et al. Synthesis of Some Novel 2,6‐Disubstituted Pyridazin‐3(2H)‐one Derivatives as Analgesic, Anti‐Inflammatory, and Non‐Ulcerogenic Agents , 2017, Archiv der Pharmazie.
[26] C. Supuran,et al. Synthesis of bulky-tailed sulfonamides incorporating pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects. , 2017, Bioorganic & medicinal chemistry.
[27] C. Supuran,et al. Design and Synthesis of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Treatment of Rheumatoid Arthritis. , 2017, Journal of medicinal chemistry.
[28] M. Akhter,et al. The therapeutic journey of pyridazinone. , 2016, European journal of medicinal chemistry.
[29] K. Hwang,et al. Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649). , 2016, Biochemical and biophysical research communications.
[30] C. Supuran,et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium , 2016, Journal of enzyme inhibition and medicinal chemistry.
[31] D. Mehta,et al. Recent Advances in Anti-inflammatory Potential of Pyridazinone Derivatives. , 2016, Mini reviews in medicinal chemistry.
[32] C. Supuran. Structure and function of carbonic anhydrases. , 2016, The Biochemical journal.
[33] C. Supuran. How many carbonic anhydrase inhibition mechanisms exist? , 2016, Journal of enzyme inhibition and medicinal chemistry.
[34] C. Supuran,et al. Pyridazinone substituted benzenesulfonamides as potent carbonic anhydrase inhibitors. , 2016, Bioorganic & medicinal chemistry letters.
[35] C. Supuran,et al. Efficient Expression and Crystallization System of Cancer-Associated Carbonic Anhydrase Isoform IX. , 2015, Journal of medicinal chemistry.
[36] P. Reddanna,et al. Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. , 2015, Protein and peptide letters.
[37] C. Supuran,et al. α-Carbonic Anhydrases Possess Thioesterase Activity. , 2015, ACS medicinal chemistry letters.
[38] Oliver Werz,et al. Multi-target approach for natural products in inflammation. , 2014, Drug discovery today.
[39] G. FitzGerald,et al. GCG100649, A Novel Cyclooxygenase‐2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase‐I/II: Preliminary Dose–Exposure Relationships to Define Clinical Development Strategies , 2013, Clinical pharmacology in drug development.
[40] F. Bihel,et al. Synthesis and antiproliferative effects of 5,6-disubstituted Pyridazin-3(2H)-ones designed as conformationally constrained combretastatin A-4 Analogues. , 2013, Anti-cancer agents in medicinal chemistry.
[41] J. Medina-Franco,et al. Shifting from the single to the multitarget paradigm in drug discovery. , 2013, Drug discovery today.
[42] J. Bajorath,et al. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors. , 2013, Bioorganic & medicinal chemistry letters.
[43] Wei Zhang,et al. Transgenic mice over-expressing carbonic anhydrase I showed aggravated joint inflammation and tissue destruction , 2012, BMC Musculoskeletal Disorders.
[44] S. Gawade. Acetic acid induced painful endogenous infliction in writhing test on mice , 2012, Journal of pharmacology & pharmacotherapeutics.
[45] Peichang Wang,et al. Carbonic Anhydrases III and IV Autoantibodies in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Diabetes, Hypertensive Renal Disease, and Heart Failure , 2012, Clinical & developmental immunology.
[46] Sui Huang,et al. Regulation of inflammation in cancer by eicosanoids. , 2011, Prostaglandins & other lipid mediators.
[47] Jinxiang Han,et al. Increased expression of carbonic anhydrase I in the synovium of patients with ankylosing spondylitis , 2010, BMC musculoskeletal disorders.
[48] J. Bajorath,et al. Atomic resolution studies of carbonic anhydrase II. , 2010, Acta crystallographica. Section D, Biological crystallography.
[49] M. Papadakis,et al. The association of spinal osteoarthritis with lumbar lordosis , 2010, BMC musculoskeletal disorders.
[50] J. Yang,et al. (118) CG100649, a novel dual-acting COX-2 and carbonic anhydrase inhibitor: Preclinical pharmacology , 2008 .
[51] C. Supuran,et al. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib. , 2006, Bioorganic & medicinal chemistry letters.
[52] G. Klebe,et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. , 2004, Journal of medicinal chemistry.
[53] G N Shah,et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[54] P. Reeh,et al. A dominant role of acid pH in inflammatory excitation and sensitization of nociceptors in rat skin, in vitro , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[55] D. Witiak,et al. Inhibitors of Cyclooxygenase and 5-Lipoxygenase , 1994, Current Medicinal Chemistry.
[56] M. Kendall,et al. Significance of the hydrogen ion concentration in synovial fluid in rheumatoid arthritis. , 1985, Clinical and experimental rheumatology.
[57] R. Khalifah,et al. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. , 1971, The Journal of biological chemistry.
[58] C A WINTER,et al. Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs , 1962, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[59] Jyoti Singh,et al. Pyridazinone: an attractive lead for anti-inflammatory and analgesic drug discovery. , 2017, Future medicinal chemistry.